Sanofi and Regeneron Pharmaceuticals have reported positive results from the Phase III clinical trial of Dupixent (dupilumab) in children aged six to 11 years with severe atopic dermatitis.

In combination with standard-of-care topical corticosteroids (TCS), the drug led to significant improvements in disease signs, symptoms, and health-related quality of life.

Dupixent is a fully-human monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) protein signalling.

According to findings from clinical trials of the drug, IL-4 and IL-13 are involved in the type 2 inflammation associated with atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP).

The randomised, double-blind, placebo-controlled Phase III trial assessed the safety and efficacy of the drug plus TCS in 367 paediatric patients with atopic dermatitis covering an average of 60% of their skin.

In the trial, the majority of participants treated with the Dupixent combination experienced clear or almost clear skin at week 16 and more than two-thirds had a minimum of 75% overall improvement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Trial principal investigator Amy Paller said: “In my practice, I see children with severe atopic dermatitis struggling with intense, persistent itching and skin lesions covering much of their body, and caregivers who are desperate for additional treatment options that can help control this disease.

“Data from the Phase III trial in children aged six to 11 adds to the established efficacy and safety data in adults and adolescents and provides hope to physicians and families for a potential new treatment option for children with this chronic disease.”

The companies reported positive top-line data from the trial in August last year.

The trial results are currently under review by regulatory agencies, including in the US, Canada and EU.